Cardiology
Conference Coverage
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.
News
Drinking black tea linked to lower risk of dying from cardiovascular disease
“While these findings may offer reassurance to tea drinkers, they do not indicate that people should start drinking tea or change their tea...
News
How do you live with COVID? One doctor’s personal experience
Early in 2020, Anne Peters, MD, caught COVID-19. The author of Medscape’s “Peters on Diabetes” column was sick in March 2020 before state-mandated...
News
VTE risk not elevated in AD patients on JAK inhibitors: Study
The labels of JAK inhibitors include a boxed warning describing an increased risk of “serious heart-related events such as heart attack or stroke...
News
ACC fills gaps on guidance for nonstatin therapies for LDL-C lowering
The new guidance addresses the role of nonstatin therapies for lowering LDL-C, which were not addressed in the 2018 ACC/AHA guideline on...
Conference Coverage
Rivaroxaban outmatched by VKAs for AFib in rheumatic heart disease
A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS...
Conference Coverage
COVID-19 vaccine safe in patients with heart failure
There should be no concern about cardiovascular side effects from mRNA vaccines in patients with HF; moreover, vaccines provide a survival benefit...
Conference Coverage
ALL-HEART: No benefit of allopurinol in ischemic heart disease
Allopurinol failed to affect a composite of nonfatal MI, nonfatal stroke, or CV death, in a randomized trial that was ‘definitively neutral’ in...
Conference Coverage
Albuminuria linked to higher CVD risk in diabetes
An analysis of more than 74,000 Danish people with type 2 diabetes showed an elevated CVD event rate in those with albuminuria.
Conference Coverage
DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening
Comprehensive cardiovascular screening fell short of significantly reducing all-cause mortality in men aged 65-74, but some benefits were seen.